Velcade — Competitive Intelligence Brief

Velcade (bortezomib) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Proteasome inhibitor. Area: Oncology.

marketed Proteasome inhibitor 26S proteasome chymotrypsin-like activity Oncology

Target snapshot

Velcade (bortezomib) — Shilpa. Reversible inhibitor of 26S proteasome chymotrypsin-like activity preventing ubiquitinated protein degradation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Velcade TARGET	bortezomib	Shilpa	marketed	Proteasome inhibitor	26S proteasome chymotrypsin-like activity	2003-01-01
Ninlaro	IXAZOMIB	Takeda	marketed	Proteasome Inhibitor	Proteasome subunit beta type-5	2015-01-01
Kyprolis	carfilzomib	Amgen	marketed	Proteasome Inhibitor [EPC]	Proteasome subunit beta type-5	2012-01-01
PAD combination	PAD combination	Cooperative Study Group A for Hematology	marketed	Combination therapy (proteasome inhibitor + immunomodulatory agent + corticosteroid)	26S proteasome; cereblon (CRBN); glucocorticoid receptor
Ixazomib plus low-dose lenalidomide	Ixazomib plus low-dose lenalidomide	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Proteasome inhibitor and immunomodulatory agent	Proteasome and cereblon
Drug: Carfilzomib + Dexamethasone	Drug: Carfilzomib + Dexamethasone	Amgen	marketed	Proteasome inhibitor + corticosteroid combination	20S proteasome (carfilzomib); glucocorticoid receptor (dexamethasone)
VRD for first-cycle induction therapy	VRD for first-cycle induction therapy	The First Affiliated Hospital of Soochow University	marketed	Proteasome inhibitor + immunomodulatory agent + corticosteroid combination	26S proteasome (bortezomib); cereblon/CRBN (lenalidomide); glucocorticoid receptor (dexamethasone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2032-11-03 — Velcade · 8962572 · Formulation · US
• 2042-09-23 — Velcade · 11752164 · Method of Use · US
• 2042-09-23 — Velcade · 11679119 · Method of Use · US
• 2042-09-23 — Velcade · 12005069 · Formulation · US

Sponsor landscape (Proteasome inhibitor class)

1. Millennium Pharmaceuticals, Inc. · 2 drugs in this class
2. Meletios A. Dimopoulos · 1 drug in this class
3. National Cancer Institute (NCI) · 1 drug in this class
4. PETHEMA Foundation · 1 drug in this class
5. Pfizer · 1 drug in this class
6. Shilpa · 1 drug in this class
7. Telik · 1 drug in this class
8. European Myeloma Network B.V. · 1 drug in this class
9. University of Arkansas · 1 drug in this class